Skip to main content

Table 2 Adverse events of the subjects

From: Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial

 

SQT (n = 195)

PBAT (n = 195)

p-value

n (%)

n (%)

Bloating

21 (22.6)

11 (15.3)

0.097

Epigastric soreness

15 (16.1)

17 (23.6)

0.854

Anorexia

2 (2.2)

1 (1.4)

1.000

Taste distortions

24 (25.8)

4 (5.6)

<0.001

Nausea

14 (15.1)

6 (8.3)

0.108

Vomiting

0

2 (2.8)

0.478

Abdominal pain

4 (4.3)

4 (5.6)

0.721

Headache

1 (1.1)

2 (2.8)

1.000

Dyspepsia

4 (4.3)

4 (5.6)

0.721

Diarrhea

2 (2.2)

12 (16.7)

0.014

Constipation

2 (2.2)

3 (4.2)

1.000

Reflux

1 (1.1)

1 (1.4)

0.478

Rash and itching

2 (2.2)

5 (2.8)

0.446

Dizziness

1 (1.1)

0

1.000

Stool color change

0

3 (4.2)

0.246

Total

93 (47.7)

72 (36.9)

0.040

  1. Bold style, means statistical significance
  2. SQT sequential therapy, PBAT quadruple therapy consist of pantoprazole, bismuth, amoxicillin, and tetracycline